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Background/aim: The aim of the study was to evaluate the protective effect of Botulinum A toxin injection against ischemia-reperfusion
injury.
Materials and methods: Thirty-two Sprague-Dawley rats were divided into: control, ischemia-reperfusion, ischemic preconditioning,
and botulinum groups. In all groups the musculocutaneous pedicle flap was occluded for 4 h, and then reperfused to induce ischemiareperfusion injury. Serum and tissue myeloperoxidase (MPO) and nitric oxide (NO) levels were measured at 24 h and at 10 days.
Results: Tissue MPO levels did not differ significantly between the ischemic preconditioning and botulinum groups at 24 h but was
significantly lower in the botulinum group at 10 days. Tissue NO levels were significantly higher in the ischemic preconditioning group
compared to the botulinum group at 24 h and at 10 days. Serum MPO showed no significant difference between these two groups at 24
h but was significantly lower in the ischemic preconditioning group compared to the botulinum group at 10 days. Serum NO levels were
not significantly different at 24 h but significantly higher in the botulinum group at 10 days.
Conclusion: Findings show that botulinum has a protective effect against the ischemia-reperfusion injury via increased NO and
decreased MPO levels in tissue. Based on tissue NO levels, ischemic preconditioning was significantly higher than botulinum.
Key words: Ischemic preconditioning, Botulinum A toxin, ischemia-reperfusion injury, musculocutaneous flap, nitric oxide,
myeloperoxidase

1. Introduction
Free or pedicled musculocutaneous flaps are used in the
closure of many complicated defects. Despite advances
in technology and surgical techniques, flap loss
following reperfusion remains a serious problem due to
ischemia-reperfusion injury (IRI) [1]. IRI occurs due to
complex mechanisms including apoptosis, production
of free oxygen radicals, platelet aggregation, complement
system activation, and leukocyte-endothelial interaction.
Surgical delay is the only realistic method clinically
shown to increase flap survival. This method causes
vascular dilation and increases blood flow in muscle
and adjacent skin tissue. Ischemic preconditioning
is a surgical delay technique that involves subjecting
tissue to a short, nonlethal period of ischemia, which

increases its resistance to damage due to subsequent
episodes of ischemia. In addition to surgical delay, many
pharmacological agents are now used to prevent IRI.
Botulinum toxin is the strongest known paralytic
agent. Botulinum A toxin has become widely used in
the treatment of conditions associated with muscle
overaction. In addition to its paralytic effect, Botulinum
A toxin also influences muscle metabolism. Matic et
al. demonstrated that Botulinum A toxin exerts effects
similar to ischemic preconditioning on muscle tissue
[2].
Therefore, this study was conducted to evaluate
the effectiveness of Botulinum A toxin injection as
a preconditioning technique to prevent IRI in rat
musculocutaneous flaps.

* Correspondence: handanderebasinlioglu@gmail.com
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2. Materials and methods
2.1. Subjects
The present study was performed in the Experimental
Animals Laboratory of İstanbul University, Cerrahpaşa
Medical School after receiving ethical approval from the
İstanbul University Local Ethics Committee. Thirty-two
female Sprague-Dawley rats with an average weight of 210
g (180–230 g) which were raised in the İstanbul University
Experimental Medicine Research Center were used in the
study. The rats were randomly separated into four groups:
control group, ischemia-reperfusion (IR) group, ischemic
preconditioning group, and the Botulinum A toxin group
(Table 1).
2.2. Surgical procedure
A dorsal paraspinal incision was made to expose the
medial edges of the latissimus dorsi muscles. The flap
of muscle with a 4 × 5 cm skin island was raised on a
thoracodorsal pedicle. To prevent detachment of skin
from the muscle, suspension sutures were placed in the
inferior and superior corners of the flap’s medial edge.
The skin island was completely circumcised to ensure
supply from the muscular perfusing vessels. While raising
the latissimus dorsi musculocutaneous flap (LDMF),
all intercostal arteries feeding the muscle were ligated
to ensure the flap was perfused exclusively through the
thoracodorsal pedicle. Without fully skeletonizing the
thoracodorsal pedicle, the surrounding muscle tissue was
thinned enough to allow clamping.
2.3. Ischemic preconditioning procedure
The ischemic preconditioning method used in this study
was based on the model described by Pang et al., in which
they demonstrated the effect of ischemic preconditioning
in porcine latissimus dorsi muscle by implementing
3 cycles of 10 min of ischemia followed by 10 min of
reperfusion [3]. Ten days after ischemic preconditioning,
the flaps were subjected to the IR procedure.
2.4. Botulinum A toxin injection
Botulinum A toxin (BOTOX ®Ireland) was delivered as an
intramuscular injection (1.4 units) to the right latissimus
dorsi muscle of 8 rats 4 weeks before the IR procedure.
This is the dose used by Çelik et al. [4].

2.5. Ischemia reperfusion procedure
Ischemia was achieved by clamping the pedicle of the
raised thoracodorsal pedicled LDMF. At the end of 4 h, the
clamp was removed to allow reperfusion.
2.6. Biochemical analyses
Serum and tissue samples obtained from the rats were
analyzed for nitric oxide (NO) and myeloperoxidase
(MPO) levels. Blood samples (5 cc) were collected from
4 rats in each group at 24 h and 10 days after reperfusion
of the LDMF. The blood samples were placed in dry tubes
and centrifuged for 4 min at 4000 rpm. The serum samples
were placed in polypropylene tubes and stored in liquid
nitrogen.
Tissue specimens were obtained by removing the entire
flap from the pedicle before decapitation of the rat. Biopsy
materials were divided into two groups vertically and half
of them were used for histopathological examination and
the other group was used for tissue MPO and NO analysis.
The tissue was wrapped in aluminum foil and frozen
in liquid nitrogen. The tissue specimens were cut with a
Heidolph electric knife into 0.2 g pieces and homogenized
for 5 min in 1 mL of phosphate buffer solution (pH 7.2).
The homogenized tissues were centrifuged for 10 min
at 5000 rpm in polypropylene tubes in a Sigma 3U18K
centrifuge (Germany). The resulting supernatants were
separated and used in analyses.
Tissue and serum NO levels were measured by
colorimetric method using Biotech Nitric Oxide Assay
Kit (Oxis Research, catalogue no: 22110, USA). Tissue
and serum MPO levels were measured using the ELISA
method using HK105 Rat MPO ELISA Kit (Hycult
Biotech,Netherlands).
2.7. Histopathological analysis
Tissue samples were collected at the 24th hour and on the
10th day, before the rats were sacrificed. Tissue samples
were formalin-fixed and embedded in paraffin after routine
tissue follow-up and 4-µm sections were taken. The
tissue samples were stained with hematoxylin eosin. The
presence of acute inflammatory cells and the proliferation
of vessels were examined in the dermis, the epidermis,
the subcutaneous tissue and the muscle tissue with a light
microscope; and also degeneration was evaluated in the

Table 1. Groups and procedures.
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The Groups

Procedures

Control group

No procedure was applied

Ischemia Reperfusion group

Ischemia reperfusion procedure

Ischemic preconditioning group

Ischemic preconditioning procedure + Ischemia reperfusion procedure

Botulinum A group

Botulinum A toxin injection + Ischemia reperfusion procedure
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muscle tissue. The histopathological above parameters
were evaluated by a single pathologist and scored between
1 and 3 (Figures 1–3). The data obtained according to this
scoring were evaluated statistically using the Kruskall–
Wallis test, the Mann–Whitney U test, and the Wilcoxon
signed rank test.
2.8. Groups
2.8.1. Control group
No treatment was performed on 8 rats in the control group.
The right latissimus dorsi muscles of these rats were raised
as a musculocutaneous flap and they were cut off from the
pedicle for tissue biopsy evaluation.
Serum MPO and NO levels were measured by applying
the procedures described above to the blood samples
taken from each rat. The values obtained were used as base
values.
2.8.2. Ischemia reperfusion group
The right latissimusdorsi muscle of 8 rats in the ischemia
reperfusion group which were raised as musculocutaneous
flaps were returned to their places after they were
subjected to ischemia reperfusion procedures described
above. MPO and NO levels were measured in blood
and tissue samples of 4 rats at the 24th hour and 4 rats
on the 10th day of ischemia reperfusion. Thus, the effect
of ischemia reperfusion injury on the parameters used
was determined. The data of the other two experimental
groups were compared with the data of this group and
their protective effects were evaluated.
2.8.3. Ischemic preconditioning group
The right latissimus dorsi musculocutaneous flap of 8 rats
in this group was raised and after ischemic preconditioning
as described above was applied flaps were returned to their
places. Ten days after the preconditioning flaps were raised
again to be subjected to ischemia reperfusion procedure
and were settled in their original places. MPO and NO
levels were measured in blood and tissue samples of 4 rats
at the 24th hour and 4 rats on the 10th day of ischemia
reperfusion. Values were compared with other groups.
2.8.4. Botulinum A toxin group
An intramuscular injection of botulinum A toxin was
administered to the right latissimus dorsi muscle of 8 rats
in this group. Four weeks after the application, the right
latissimus dorsi musculocutaneous flap was raised in order
to perform the IR procedure and the flaps were returned to
their places. MPO and NO levels were measured in blood
and tissue samples of 4 rats at the 24th hour and 4 rats
on the 10th day of IR. Values were compared with other
groups.
2.9. Statistical analysis
Number Cruncher Statistical System 2007 & Power
Analysis and Sample Size 2008 Statistical Software (Utah,
USA) program was used for the statistical analyses of

Figure 1. Grade 1 acute inflammation in muscle tissue.

Figure 2. Grade 2 acute inflammation in muscle tissue.

Figure 3. Grade 3 acute inflammation in muscle tissue.
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biochemical values. In addition to descriptive statistical
methods (mean, standard deviation, and median), the
Kruskal–Wallis test was used in comparisons between
groups because the variables did not meet normal
distribution criteria due to the number of subjects in each
group. The Mann–Whitney U test was used to determine
the group responsible for the difference. Bonferroni
correction after multiple comparisons was not made in
this study. Significance was evaluated at the level of P <
0.05.
3. Results
3.1. Tissue myeloperoxidase levels
Mean tissue MPO levels at 24 h were 0.38 ± 0.23 µmol/g
wet tissue in the control group, 1.36 ± 0.12 µmol/g in the
IR group, 1.06 ± 0.07 µmol/g in the preconditioning group,
and 1.13 ± 0.03 µmol/g in the Botulinum A toxin group.
There was a statistically significant difference among the
groups (P < 0.01). MPO levels were significantly higher in
the IR, preconditioning, and Botulinum A toxin groups
when compared to the control group (P < 0.01) and
in the IR group compared to the preconditioning and

Botulinum A toxin groups (P < 0.01). MPO levels in the
preconditioning and Botulinum A toxin groups did not
differ significantly (P > 0.05).
At 10 days, mean tissue MPO levels were 0.38 ± 0.23
µmol/g wet tissue in the control group, 1.15 ± 0.06 µmol/g
in the IR group, 1.12 ± 0.07 µmol/g in the preconditioning
group, and 0.98 ± 0.09 µmol/g in the Botulinum A
toxin group (P < 0.01). Mean MPO levels at 10 days
were significantly higher in the IR, preconditioning, and
Botulinum A toxin groups compared to the control group
(P < 0.01). No significant difference was found between day
10 tissue MPO levels in the IR and preconditioning groups
(P > 0.05), while the Botulinum A toxin group showed
significantly lower levels compared to the IR group (P <
0.05). Tissue MPO levels were significantly higher in the
preconditioning group than the Botulinum A toxin group
(P < 0.05).
The IR group showed a significant decrease in tissue
MPO levels at day 10 compared to 24 h (P < 0.05). The
difference between the tissue MPO levels at 24 h and
10 days was not significant in the preconditioning and
Botulinum A toxin groups (P > 0.05) (Table 2).

Table 2. Tissue myeloperoxidase measurements.
Myeloperoxidase
Tissue levels
24th hour

Myeloperoxidase
tissue levels
10th day

Avarege

0.38

0.38

SD

0.23

0.23

Median

0.29

0.29

Avarege

1.36

1.15

SD

0.12

0.06

Median

1.36

1.17

Avarege

1.06

1.12

SD

0.07

0.07

Median

1.04

1.15

Avarege

1.13

0.98

SD

0.03

0.09

Median

1.13

0.98

(microgram\
gramwettissue)
Control

IR

Delay

Botox
P

0.001**

0.001**

Control-IR

0.004**

0.004**

Control-Delay

0.004**

0.004**

Control-Botox

0.004**

0.004**

IR-Delay

0.009**

0.295

IR-Botox

0.009**

0.016*

Delay-Botox

0.095

0.032*

b
c
c
c
c
c
c

Wilcoxon signed rank test
Mann–Whitney U test

a
c
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Kruskal–Wallis test
*P < 0.05		
**P < 0.01

b

P

a

-

0.043*

0.279

0.068
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3.2. Tissue nitric oxide levels
Mean tissue NO levels at 24 h were 0.68 ± 0.24 µmol/g wet
tissue in the control group, 0.88 ± 0.17 µmol/g in the IR
group, 1.97 ± 0.26µmol/g in the preconditioning group,
and 1.62 ± 0.10 µmol/g in the Botulinum A toxin group
(P < 0.01). While no significant difference was detected
between the control and IR groups (P > 0.05), tissue NO
levels were significantly higher in the preconditioning
and Botulinum A toxin groups when compared to the
control group (P < 0.01) and the IR group (P < 0.01).
Tissue NO level at 24 h was also significantly higher in
the preconditioning group compared to the Botulinum A
toxin group (P < 0.05).
At 10 days, mean tissue NO levels were 0.68 ± 0.24
µmol/g in the control group, 1.6 ± 0.14 µmol/g in the
IR group, 1.97 ± 0.04 µmol/g in the preconditioning
group, and 0.81 ± 0.31 µmol/g in the Botulinum A toxin
group (P < 0.01). The IR and preconditioning groups
showed significantly higher levels of tissue NO on day 10
compared to the control group (P < 0.01), whereas the
difference between the Botulinum A toxin and control

groups was nonsignificant (P > 0.05). Mean day 10 tissue
NO level in the IR group was significantly lower than in
the preconditioning group and significantly higher than in
the Botulinum A toxin group (P < 0.01). Mean NO level
was also significantly higher in the preconditioning group
compared to the Botulinum A toxin group (P < 0.01).
The IR group showed a significant increase in tissue NO
levels between 24 h and 10 days (P < 0.05). A statistically
significant change was not seen in the preconditioning
group between 24 h and 10 days (P > 0.05). The Botulinum
A toxin group showed a significant decrease in tissue NO
levels between 24 h and 10 days (P < 0.05) (Table 3).
3.3. Serum myeloperoxidase levels
Mean serum MPO levels at 24 h were 319.77 ± 7.52 ng/
mL in the control group, 416.42 ± 15.75 ng/mL in the
IR group, 466.42 ± 15.75 ng/mL in the preconditioning
group, and 470.46 ± 5.65 ng/mL in the Botulinum A toxin
group (P < 0.01). Serum MPO levels were significantly
higher in the IR, preconditioning, and Botulinum A toxin
groups compared to the control group (P < 0.01) and in the
preconditioning and Botulinum A toxin groups compared

Table 3. Tissue nitric oxide measurements.
Nitric oxide
tissue levels
24th hour

Nitric oxide
Tissue levels
10th day

Average

0.63

0.63

SD

0.24

0.24

Median

0.55

0.55

Average

0.88

1.63

SD

0.17

0.14

Median

0.90

1.60

Average

1.97

1.97

SD

0.26

0.04

Median

1.97

1.99

Average

1.62

0.81

SD

0.10

0.31

Median

(micromole
\gramwettissue)

Control

IR

Delay

Botox

1.62

0.81

P

0.001**

0.001**

Control-IR

0.104

0.004**

Control-Delay

0.004**

0.004**

Control-Botox

0.003**

0.372

IR-Delay

0.009**

0.009**

IR-Botox

0.009**

0.009**

Delay-Botox

0.036*

0.009**

b
c
c
c
c
c
c

Wilcoxon signed rank test
Mann–Whitney U test

a
c

P

a

-

0.043*

0.893

0.043*

Kruskal–Wallis test
*P < 0.05		
**P < 0.01
b

1527

DEREBAŞINLIOĞLU et al. / Turk J Med Sci
to the IR group (P < 0.01). No significant difference in 24
h serum MPO was detected between the preconditioning
and Botulinum A toxin groups (P > 0.05).
At 10 days, mean serum MPO levels were 319.77 ±
7.52 ng/mL in the control group, 451.62 ± 14.10 ng/mL in
the IR group, 441.02 ± 1.62 ng/mL in the preconditioning
group, and 457.14 ± 10.98 ng/mL in the Botulinum A
toxin group (P < 0.01). Mean day 10 serum MPO levels
were significantly higher in the IR, preconditioning,
and Botulinum A toxin groups compared to the control
group (P < 0.01). Although the differences between the
IR group and the preconditioning and Botulinum A toxin
groups did not reach statistical significance (P > 0.05),
serum MPO levels on day 10 were significantly lower
in the preconditioning group when compared with the
Botulinum A toxin group (P < 0.05).
In the preconditioning group, serum MPO was
significantly lower at 10 days compared to values at 24 h
(P < 0.05). In the IR and Botulinum A toxin groups, no
statistically significant change in serum MPO occurred
between 24 h and 10 days (P > 0.05) (Table 4).

3.4. Serum nitric oxide levels
Mean serum NO levels at 24 h were 17.56 ± 4.22 µmol/L
in the control group, 15.36 ± 3.02 µmol/L in the IR group,
42.70 ± 3.58 µmol/L in the preconditioning group, and
46.52 ± 5.90 µmol/L in the Botulinum A toxin group
(P < 0.01). There was no significant difference between
the control and IR groups (P > 0.05), while serum NO
levels were significantly higher in the preconditioning
and Botulinum A toxin groups compared to the control
group (P < 0.01). Accordingly, serum NO levels were
significantly higher in the preconditioning and Botulinum
A toxin groups when compared to the IR group (P < 0.01).
However, 24 h serum NO levels did not differ significantly
between the preconditioning and Botulinum A toxin
groups (P > 0.05).
On day 10, mean serum NO levels were 17.56 ± 4.22
µmol/L in the control group, 22 ± 3.67 µmol/L in the IR
group, 25.09 ± 3.04 µmol/L in the preconditioning group,
and 35.84 ± 2.59 µmol/L in the Botulinum A toxin group
(P < 0.01). While no statistical significant difference was
detected between the control and IR groups (P > 0.05),

Table 4. Serum myeloperoxidase measurements.
Myeloperoxidase
Serum levels
24th hour

Myeloperoxidase
Serum levels
10th day

Average

319.77

319.77

SD

7.52

7.52

Median

319.40

319.40

Average

416.42

451.62

SD

15.75

14.10

Median

416.42

454.00

Avarege

466.42

441.02

SD

9.78

1.62

Median

466.80

440.30

Average

470.46

457.14

SD

5.65

10.98

Median

(nanogram\milliliter)

Control

IR

Delay

Botox

470.80

458.80

P

0.001**

0.002**

Control-IR

0.006**

0.006**

Control-Delay

0.006**

0.006**

Control-Botox

0.006**

0.006**

IR-Delay

0.009**

0.117

IR-Botox

0.009**

0.402

Delay-Botox

0.295

0.047*

b
c
c
c
c
c
c

Wilcoxon signed rank test
Mann–Whitney U test

a
c
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Kruskal–Wallis test
*P < 0.05		
**P < 0.01

b

P

a

-

0.080

0.043*

0.080
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both the preconditioning and Botulinum A toxin groups
had significantly higher levels when compared with the
control group (P < 0.01). No significant difference in day
10 serum NO levels was detected between the IR and
preconditioning group (P > 0.05), whereas the IR group
had significantly lower levels than the Botulinum A toxin
group (P < 0.01) and the preconditioning group had
significantly lower levels compared to the Botulinum A
toxin group (P < 0.01).
The IR group showed a significant increase in serum
NO levels at 10 days compared to 24 h (P < 0.05), while the
preconditioning and Botulinum A toxin groups exhibited
significant decreases (P < 0.05) (Table 5).
3.5. Histopathological result
In the group subjected exclusively to ischemia-reperfusion,
the distal portion of the flap exhibited minimal necrosis
and loss of muscle tissue under macroscopic examination
as well as microscopic ulceration and necrosis in the
epidermis on day 10. Macroscopic or microscopic necrosis
was not observed in the other groups (Figures 4–6).
According to the histopathological examination, acute

inflammation of the Botulinum A toxin group of dermis
tissue was more severe than the IR group at the 24th hour
and on the 10th day. The acute inflammation at the 24th
hour and on the 10th day in the Botulinum A toxin group
of muscle tissue was less than the IR group, but more
severe than the preconditioning group.
In the biopsy taken from the Botulinum A toxin group
at 24 h, more vascularization was observed in the dermis
layer compared to the control group. The vascularization
of the muscle tissue was similar to the control group at the
24th hour, but vascularity in the Botulinum A toxin group
was higher than the control group on the 10th day.
On the 10th day, muscle degeneration in the
preconditioning group was higher than the IR and the
Botulinum A toxin groups.
4. Discussion
With the discovery that Botulinum A toxin inhibited
acetylcholine release in motor neurons, Botulinum A
toxin began to be used in the treatment of many diseases.
When the molecular structure and mechanism of action

Table 5. Serum nitric oxide measurements.
Nitric oxide
serum levels
24th hour

Nitric oxide
serum levels
10th day

Average

17.56

17.56

SD

4.22

4.22

Median

18.80

18.80

Average

15.36

22.00

SD

3.02

3.67

Median

15.50

22.00

Average

42.70

25.09

SD

3.58

3.04

Median

42.30

25.50

Average

46.52

35.84

SD

5.89

2.59

Median

(micromole\liter)

Control

IR

Delay

Botox

46.70

36.70

P

0.001**

0.001**

Control-IR

0.255

0.123

Control-Delay

0.004**

0.007**

Control-Botox

0.004**

0.004**

IR-Delay

0.009**

0.117

IR-Botox

0.009**

0.009**

Delay-Botox

0.347

0.009**

b
c
c
c
c
c
c

Wilcoxon signed rank test
Mann–Whitney U test

a
c

P

-

0.043*

0.043*

0.043*

Kruskal–Wallis test
*P < 0.05		
**P < 0.01
b
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Figure 5. Rat pedicled latissimus dorsi musculocutaneous flap
10 days after ischemic preconditioning followed by ischemiareperfusion (silk-marked tip distal margin).
Figure 4. Rat pedicled latissimus dorsi musculocutaneous flap
10 days after exposure to ischemia-reperfusion (silk-marked tip
distal margin).

of the toxin was later understood, experimental studies
demonstrated that the toxin affects not only motor neurons
but also the autonomous nervous system. Sympathetic
stimulation of vessels initially causes vasodilatation due to
the effect of NE on β1 receptors and later vasoconstriction
due to α2 receptor activation. Botulinum A toxin has
been shown to reduce NE-mediated vasoconstriction [5].
Perivascular administration of Botulinum A toxin increases
vessel diameter and tissue circulation [2,6]. This suggests
the possible utility of botulinum toxin in flap surgery to
increase flap survival. Botulinum A toxin was found to
increase flap survival in subcutaneous applications [7,8].
Preconditioning has been shown in multiple studies
to clinically increase flap survival [9,10]. This technique
provides late phase protection against skeletal muscle
necrosis and requires multiple IR cycles [11]. However,
disadvantages of this method include the need for an
additional surgical session to perform the preconditioning
procedure and the subsequent increases in length of
hospital stay, infection risk, and cost.
Matic et al. investigated the effects of Botulinum A
toxin on muscle metabolism in rabbit masseter muscle.
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They reported increases in blood flow, blood volume,
permeability surface area product, and glucose uptake
in the muscle following botulinum toxin injection [2].
Clinical studies showed that surgical delay procedure
increased the blood flow in muscle and adjacent skin
tissue [12]. Although tissue subjected to ischemic
preconditioning alters its energy metabolism to decrease
energy need [3,13], glucose uptake in muscle tissue
increases after botulinum injection [2]. These phenomena
are contradictory.
In our study, macroscopic tissue necrosis was not
observed in the Botulinum A toxin or the ischemic
preconditioning group. In the group subjected exclusively
to IR, the distal portion of the flap exhibited minimal
necrosis and loss of muscle tissue on macroscopic
examination, as well as microscopic ulceration and
necrosis in the epidermis on day 10. In composite flaps, it
has been shown that extended ischemia can cause muscle
necrosis with no loss of skin vitality [14].
Eun et al. evaluated the protective effect of
erythropoietin against IRI in musculocutaneous flaps. At
24 h, they detected lower MPO levels and higher NO levels
in the erythropoietin-treated group compared to the group
subjected to ischemia-reperfusion only. MPO level was
evaluated as an indicator of neutrophil infiltration, and the
authors concluded that erythropoietin protected against
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Figure 6. Rat pedicled latissimus dorsi musculocutaneous flap
10 days after Botulinum A injection followed by ischemiareperfusion (silk-marked tip distal margin).

IRI by reducing inflammation and neutrophil infiltration
and increasing tissue NO levels [15]. In the present study,
we also considered elevated NO levels detected with
colorimetric method and reduced MPO levels detected
with ELISA method as a protective mechanism against IRI.
Endothelium produces NO, a well-known protective
mediator against IRI [14]. NO is synthesized from the
guanidinium group of L-arginine by NO synthetases
(NOS). NO is an important chemical agent with various
biological functions such as endothelium-dependent
vasodilatation, clearing oxygen radicals, inhibiting platelet
aggregation, and reducing leukocyte-endothelial adhesion
[16]. Researchers have observed that while the use of NO
synthetases inhibitor increased flap necrosis, L-arginine
increased flap vitality [17].
In our study, tissue and serum NO levels were measured
at 24 h and 10 days after IR. NO levels at 24 h were
significantly higher in the groups that underwent ischemic

preconditioning and Botulinum A toxin injection, with
a greater increase in the preconditioning group. This
suggests that while the protective effect of NO against IRI
was present in both groups, ischemic preconditioning
was superior to Botulinum A toxin. Although the IR-only
group showed a statistically significant increase in tissue
NO values on day 10, this increase was also observed in
the serum values.
Ischemic preconditioning is evaluated in two periods,
early protection (first window) and late protection (second
window), and NO is involved in both. The effects of early
preconditioning emerge within minutes of reperfusion
and last for 2–3 h. The effects of late preconditioning
become evident 12–24 h after reperfusion and last 2–3
days [18]. Xuan et al. showed that in tissue subjected to
preconditioning, the postischemia release of NO during
the first hours is based on endothelial NOS, while the
NO released during the second window was mainly
produced by late activation of macrophage-inducible NOS
[19]. Other authors argued that endothelial NOS acts
as a trigger and inducible NOS as a late-stage mediator
[20]. According to our findings, the change in tissue NO
levels between hour 24 and day 10 in the preconditioning
group was statistically insignificant. This suggests that the
protective effect of the preconditioning method seen at
hour 24 was fully maintained on day 10.
Increased inducible NOS (iNOS) level following
cutaneous Botulinum A toxin injection has been
demonstrated by polymerase chain reaction (PCR) [21]. It
was also shown that Botulinum A toxin increases survival
of rat dorsal skin flaps [7]. In another study, histological
examination revealed an increase in vessel diameter and
neovascularization following cutaneous Botulinum A
toxin injection. PCR was also used to show that vascular
endothelial growth factor, which causes endothelial
proliferation, was increased following Botulinum A toxin
injection, along with vasodilatation, CD 31 (PECAM1
platelet-endothelial cell adhesion molecule) and iNOS
[21]. The high tissue NO levels measured at 24 h in the
Botulinum A toxin group compared to the control and IR
groups may show the protective effect of the Botulinum A
toxin against IRI by increasing NO levels.
In the literature, it has been proposed that the
functional cut-off from the target organ that occurs during
temporary muscle paralysis following intramuscular
Botulinum A toxin injection may stimulate NO synthesis
in motor neurons to preserve axonal vitality and ensure
cell survival, resulting in a local increase in NO [22]. In
complete ischemia, nerve function rapidly deteriorates
within 30 to 90 min [23]. The degree of neural tissue
damage occurring during ischemia is related to ischemia
duration and blood flow during this period [24]. In our
study, there was a significant decrease in tissue NO levels
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in the Botulinum A toxin group between 24 h and 10 days.
This may be attributed to reduced neuronal release of NO
due to IRI. These findings indicate that the NO-mediated
protective effect of Botulinum A toxin decreased at 10 days.
However, serum NO values in the Botulinum A toxin group
were substantially higher the day 10 compared to the other
groups. This shows that vessel proliferation increases NO
levels in the blood. However, a problem preventing the
movement of NO into the tissue could explain the reduced
local effect of Botulinum A toxin. Moreover, considering
that MPO activity leads to NO consumption [25], the high
serum MPO levels in the Botulinum A toxin group on
day 10 suggest that MPO may have inactivated NO before
it could act in the tissue. This may mean that the oxidantantioxidant equilibrium is restored within 10 days of IR and
this is another reason for NO reduction.
Myeloperoxidase is the green hemoprotein enzyme
found in the azurophilic granules of polymorphonuclear
leukocytes (PML). MPO enzymes turn H2O2 to HClO
(hypochlorous radical) in the presence of Cl. HClO is a
strong oxidant agent, and kills the cell via protein and lipid
peroxidation [26]. MPO measurement is used to calculate
PML content and to measure inflammation in tissues such
as the skin, eye, liver, and intestine [25]. MPO activity in
the skin is a marker of neutrophil infiltration of the flap
[13]. High MPO activity indicates NO consumption and
the onset of endothelial dysfunction [27]. In our study,
tissue and serum MPO levels measured at 24 h and 10 days
after IR showed significantly lower tissue MPO levels in
the control group compared to each of the other three IR
groups. This shows the presence of neutrophil-mediated
tissue damage in all of the three ischemia reperfusion
groups. In statistical analyses, the Botulinum A toxin and
preconditioning groups had significantly lower tissue MPO
levels when compared with the ischemia-reperfusion group.
This indicates lower levels of neutrophil-mediated tissue
damage in the treated groups. Serum MPO is believed to be
released into the vascular lumen by activated leukocytes and
then pass into the vascular tissue independent of neutrophil
extravasation. MPO is rapidly delivered to the endothelial
cell via transcytosis, accumulates in the subendothelial zone,
and exerts its effect in the vessel wall [25]. Kinetic studies
have shown that MPO acts as a solvent pool for NO. It was
shown that MPO decreases NO-dependent vasodilatation
in isolated arteries and reduces NO bioavailability in
cell cultures [28]. In our study, serum MPO levels at 24
h and 10 days were significantly higher in the IR group,
preconditioning group, and Botulinum A toxin groups when
compared with the control group. This indicates systemic
neutrophil activation in these groups. The fact that this
increase was more prominent in the preconditioning and
Botulinum A toxin groups, illustrates the lack of correlation
between tissue and serum MPO levels. Although the
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preconditioning method is reported to reduce the release
of activated neutrophils [29], the high serum MPO levels
in our study indicate the presence of activated leukocytes
in the systemic circulation. The effect of Botulinum A
toxin on neutrophils remains unknown. Considering
that NO reduces leukocyte-neutrophil adhesion [30],
preconditioning and Botulinum A toxin injection may
reduce neutrophil adhesion by increasing NO, thus
preventing neutrophil infiltration into the tissue. This may
be interpreted as another mechanism preventing MPO
transcytotic transport to endothelial tissue. Alternatively,
MPO may be eliminated somehow by being released from
tissue into the blood. It is not currently possible to state
whether it is a local effect or a systemic one. MPO levels
in the preconditioning group were markedly lower on day
10 compared to those at 24 h. This shows that although
endothelial dysfunction and systemic neutrophil activity
were somewhat decreased, the statistical nonsignificance of
this reduction compared to the IR and Botulinum A toxin
group indicates that neutrophil activation and endothelial
dysfunction measured at 24 h persisted at nearly the same
level on day 10 in these two groups.
When all these data are taken into account, ischemic
preconditioning and Botulinum A toxin have similar
biochemical effects in the prevention of IRI on days 1 and
10. Our finding of lower MPO levels in the Botulinum A
toxin group compared to the preconditioning group at 10
days may show that the Botulinum A toxin continued to
protect the tissue from neutrophil-mediated damage on
day 10, while the relatively lower tissue NO level in the
Botulinum A group may indicate a reduced protective effect
of NO or reestablishment of oxidant-antioxidant balance.
Because serum MPO and NO levels have not been
used previously to evaluate IRI, our analysis of these values
was based on intergroup comparisons and interpretation.
Additional studies are needed for sounder analyses. As
the present study was limited to 10 days, it precludes a full
evaluation of tissue damage and highlights the need for
longer-term studies. Although it has been stated that the
duration of primary ischemia in musculocutaneous flaps is
9 h and secondary critical ischemia duration is 11 h [14],
ischemia has been applied to musculocutaneous flaps for
4 h in experimental IR studies and resulted in macroscopic
necrosis [31]. While it is emphasized in the literature that
the presence of live skin tissue in flaps subjected to extended
ischemia causes loss of muscle tissue viability [14], we did
not observe gross necrosis in the present model in the IRonly group. Therefore, the use of an alternative model may
be suggested for long-term studies.
Park et al. reported that Botulinum A toxin
had a significant protective effect against IRI in a
musculocutaneous flap model [32]. In our study, we
compared Botulinum A toxin injection with the ischemic
preconditioning procedure and determined that Botulinum
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A toxin protected against the IRI via increased NO and
decreased MPO levels in the muscle tissue. According to
tissue NO levels, preconditioning was superior to Botulinum
A toxin, but we are unable to explain the high serum NO
levels in the Botulinum A toxin group. Macroscopically,
the flaps treated with Botulinum A toxin showed less
contraction than flaps in the other groups (Figures 4 –
6). Çelik et al. showed previously that Botulinum A toxin
injection is a useful method for stabilizing pedicled muscle
flaps [4]. These effects could be considered an advantage of
Botulinum A toxin.

In conclusion, Botulinum A toxin shows a protective
effect against IRI in musculocutaneous flaps. Tissue
MPO levels at 24 h suggest that ischemic preconditioning
and Botulinum A toxin injection have equal protective
effect, whereas Botulinum A toxin injection is superior
to ischemic preconditioning at day 10. However, tissue
NO levels indicate that ischemic preconditioning offers
superior protection against IRI at both 24 h and 10 days.
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